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Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we
investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats.
Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by
paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in
macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor
activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indi-
cation for polaprezinc in the prevention of paclitaxel-induced neuropathy.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Paclitaxel, an anticancer drug, is widely used for the treatment
of many types of solid tumor. However, it frequently causes pe-
ripheral neuropathy. Since this neurotoxicity is a dose-limiting side
effect, and preventive strategies have not yet been established, it
remains amajor clinical limitation of paclitaxel chemotherapy (1,2).
Paclitaxel induces the expression of proinﬂammatory cytokines
such as interleukin-1 (IL-1) and tumor necrosis factor (TNF) in rat
dorsal root ganglion (DRG) (3). Intrathecal IL-1 receptor antagonist
and plasmid DNA encoding interleukin-10 (IL-10), an anti-
inﬂammatory cytokine, reverse paclitaxel-induced mechanical
allodynia in rats (3). Though the mechanisms of paclitaxel-induced
peripheral neuropathy have yet to be fully elucidated, inﬂamma-
tory cytokines may be involved in the pathogenesis of this side
effect. In general, inﬂammatory cytokines are produced and
released by activated macrophages, and macrophage migration is
caused by inﬂammatory mediators including chemokines (4).
Polaprezinc, a zinc complex of L-carnosine that protects the
gastric mucosa, is widely used for the treatment of gastric ulcer (5).
Zinc has been shown to down-regulate proinﬂammatory cytokine-
induced nuclear factor-kappa B (NF-kB) activation (6). Recently,yushu University Hospital, 3-
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d/4.0/).zinc supplementation has been reported to alleviate peripheral
neuropathy in diabetic rats (7). However, the effect of polaprezinc
on paclitaxel-induced peripheral neuropathy remains unknown. In
this study, we investigated the preventive effect of polaprezinc on
paclitaxel-induced mechanical allodynia in rats. Moreover, we
examined the effects of paclitaxel and polaprezinc on macrophage
migration in rat DRG cells. Finally, we investigated the effect of
polaprezinc on the anti-tumor activity of paclitaxel in cultured cell
lines and tumor-bearing mice.
Male Sprague-Dawley rats weighing 200e250 g (Kyudo Co.,
Tosu) and male C57/BL6 mice weighing 15e20 g (Kyudo Co.) were
used in this study. Rats and mice were housed in groups of four to
ﬁve per cage with lights on from 07:00 AM to 07:00 PM. Animals
had free access to food and water in their home cages. All experi-
ments were approved by the Experimental Animal Care and Use
Committee of Kyushu University, and were conducted in accor-
dance with National Institutes of Health guidelines as well as the
International Association for the Study of Pain (IASP) Committee for
Research and Ethical Issues guidelines for animal research (8).
Paclitaxel (Taxol®; 6 mg/mL in Cremophor EL/ethanol 1:1) was
obtained from Bristol-Myers Squibb (Tokyo). Polaprezinc was ob-
tained from ZERIA Pharmaceutical Co., Ltd (Tokyo) and was sus-
pended in 0.1% carboxymethyl cellulose-Na. Paclitaxel (4 mg/kg) or
vehicle (50% Cremophor EL/ethanol) was administered intraperi-
toneally (i.p.) in volumes of 1 mL/kg, four times over 1 week (on
days 1, 3, 5, and 7). The dose of paclitaxel was chosen based on anese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Effect of polaprezinc on paclitaxel-induced mechanical allodynia by the von
Frey test in rats. Paclitaxel (4 mg/kg) was administered i.p. four times (on days 1, 3, 5,
and 7). Polaprezinc (3 mg/kg) was administered p.o. once daily for 7 days. The von Frey
test was performed prior to the ﬁrst drug administration (day 0) and on days 2, 4, 6,
and 8. Values are expressed as the mean ± S.E.M. of 5e7 animals. *P < 0.05 compared
with vehicle. yP < 0.05 compared with paclitaxel alone.
Fig. 2. Effects of paclitaxel and polaprezinc on macrophage migration in rat DRG cells.
Paclitaxel (4 mg/kg) was administered i.p. four times (on days 1, 3, 5, and 7). Polap-
rezinc (3 mg/kg) was administered p.o. once daily for 7 days. On day 2, 4, or 8, lumbar
L4-6 DRG were harvested and samples were immunostained with anti-CD68 antibody
for imaging of macrophages as green ﬂuorescence areas. (A) Original
magniﬁcation 200 for all images; scale bar, 100 mm. (B) Macrophage migration was
calculated by dividing the number of macrophage (CD68-positive cells) by DRG cell
area. Results are expressed as the mean ± S.E.M. of 6e11 experiments. **P < 0.01
compared with vehicle, yyP < 0.01 compared with paclitaxel alone.
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(p.o.) once daily for 7 days. The dose of polaprezinc was calculated
from the clinical dose.
Mechanical allodynia was assessed using the von Frey test, prior
to the ﬁrst drug administration and on days 2, 4, 6, and 8. On days 2,
4, and 6, the test was performed before drug administration. Each
rat was placed in a clear plastic box (20  17  13 cm) with a wire
mesh ﬂoor and allowed to habituate for 30min prior to testing. Von
Frey ﬁlaments (The Touch Test Sensory Evaluator Set; Linton
Instrumentation, Norfolk, UK) ranging from 1 to 15 g bending force
were applied to the midplantar skin of each hind paw, with each
application held for 6 s. The paw withdrawal threshold was
determined by a modiﬁed up-down method (10).
After perfusion ﬁxation of rats anesthetized with isoﬂurane
(Escain®, Pﬁzer Japan Inc., Tokyo) by 4% paraformaldehyde (PFA),
lumbar L4-6 DRG were removed on day 2, 4, or 8 and immersed in
4% PFA followed sequentially by 10%, 20%, and 30% sucrose buffer.
DRG frozen blocks were prepared using optimal cutting tempera-
ture compound (Sakura Finetek Japan Co., Ltd., Tokyo). DRG frozen
sections (thickness: 10 mm) were cut on a cryostat, ﬁxed using 4%
PFA for 15min, and blocked in 5% skimmilk for 1 h before overnight
incubation at 4 C with anti-CD68 antibody (GeneTex, Irvine, CA,
USA). DRG sections were then incubated for 2 h with Alexa Fluor®
488-conjugated anti-mouse IgG (HþL), F (ab0) 2 fragment, mounted
in 80% glycerol, and viewed under a ﬂuorescence microscope
(Keyence Co., Ltd, Osaka). Macrophage migration was calculated by
dividing the number of macrophage (CD68-positive cells) by DRG
cell area measured using image analysis software (Image J 1.45).
A549 cells (Japanese Collection of Research Bioresources Cell
Bank, Osaka), Walker 256 cells (WRC256, American Type Culture
Collection, Walkersville, MD, USA), and Lewis lung carcinoma (LLC)
cells (RIKEN BioResource Center, Ibaraki) were used in this study.
All cell lines were cultured according to a previous report (11).
A549 and Walker 256 cells were seeded at a density of 4  104
cells/cm2 onto 24-well plates and used for experiments on the
following day. Cells were exposed to Cremophor EL þ ethanol,
paclitaxel (100 ng/mL) or polaprezinc (10, 30, or 100 mM) for 6, 12,
24, 48, or 72 h. The drugs were dissolved in medium prior to
exposure. Cell viability was assessed by the mitochondrial activity
that reduced WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium, mono-
sodium salt) to formazan (11).
LLC cells (1.5 106 cells permouse in 50 mL serum-freemedium)
were implanted subcutaneously in the chests of C57/BL6 mice.
Three days after implantation, administration of drugs was initi-
ated. Paclitaxel (6 mg/kg, i.p.) and polaprezinc (3 mg/kg, p.o.) were
injected once daily for 12 days. The resulting tumor volumes were
calculated as follows: volume (mm3) ¼ 1/2  length (mm) width
(mm)2.
Values were expressed as the mean ± S.E.M. Results were
analyzed by Student's t-test or one-way analysis of variance
(ANOVA) followed by the TukeyeKramer post-hoc test to deter-
mine differences among the groups (StatView; Abacus Concepts,
Berkeley, CA, USA). A P value of less than 0.05 was considered
statistically signiﬁcant.
Paclitaxel (4 mg/kg, i.p.) signiﬁcantly reduced the paw with-
drawal threshold compared with vehicle on days 4, 6, and 8
(P < 0.05, Fig. 1). Repeated administration of polaprezinc (3 mg/kg,
p.o.) signiﬁcantly inhibited the paclitaxel-induced reduction in the
withdrawal threshold (P < 0.05).
Macrophages increased around DRG cells after paclitaxel
administration (Fig. 2A). Macrophage migration signiﬁcantly
increased on day 8 (P < 0.01, Fig. 2B). Polaprezinc completely
suppressed the paclitaxel-induced increase in macrophage migra-
tion (P < 0.01).
C
el
l 
ytilibaiv
non fo 
%(
-
)tne
mtaert
0
20
40
60
80
100
0 12 24 36 48 60 72
Paclitaxel
Paclitaxel + Polaprezinc (10 mM)
Paclitaxel + Polaprezinc (30 mM)
Paclitaxel + Polaprezinc (100 mM)
0
20
40
60
80
100
120
0 12 24 36 48 60 72
Paclitaxel
Paclitaxel + Polaprezinc (10 mM)
Paclitaxel + Polaprezinc (30 mM)
Paclitaxel + Polaprezinc (100 mM)
(B)
0
200
400
600
800
1000
1200
0 3 6 9 12 15 18
Vehicle
Paclitaxel
Paclitaxel + Polaprezinc (3 mg/kg)
m
m( e
mulov r o
muT
3 )
(C)
(A)
*
* **
*
C
el
l v
ia
bi
lit
y
(%
 o
f n
on
-tr
ea
tm
en
t)
[h] [h]
[day]
Fig. 3. Effect of polaprezinc on the anti-tumor activity of paclitaxel. (A) A549 and (B) Walker 256 cells were incubated with paclitaxel (100 ng/mL) for 6, 12, 24, 48, or 72 h in the
presence or absence of various concentrations of polaprezinc. Cell viability was measured byWST-8 assay. Results are expressed as percentages of control group viability (n ¼ 3). (C)
LLC cell-implanted mice were treated with paclitaxel (6 mg/kg, i.p.) and polaprezinc (3 mg/kg, p.o.) once daily for 12 days. Results are expressed as the mean ± S.E.M. of 5e7 animals.
*P < 0.05, **P < 0.01 compared with vehicle.
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decrease in cell viability in cultured A549 and Walker 256 cells
(Fig. 3A and 3B). Treatment with polaprezinc (10, 30, or 100 mM)
had no effect on paclitaxel-induced inhibition of tumor growth. In
tumor cell-implanted mice, paclitaxel (6 mg/kg, i.p.) signiﬁcantly
inhibited the increase in tumor volume compared with vehicle at
days 15 and 18 (P < 0.05, Fig. 3C). Treatment with polaprezinc
(3 mg/kg, p.o.) had no effect on paclitaxel-induced inhibition of
tumor growth.
In this study, repeated administration of polaprezinc inhibited
the development of paclitaxel-induced mechanical allodynia.
Therefore, polaprezinc may be beneﬁcial for the prevention of
paclitaxel-induced peripheral neuropathy.
Furthermore, we found that paclitaxel increased macrophage
migration in rat DRG cells. The macrophage migration is caused by
inﬂammatory mediators, including chemokines (4). Paclitaxel has
been reported to induce the expression of proinﬂammatory cyto-
kines, including IL-1 and TNF, in rat DRG (3). Therefore, the
paclitaxel-induced increase in macrophage migration may be
caused by chemokines or inﬂammatory cytokines induced by
paclitaxel. On day 4, paclitaxel induced mechanical allodynia but
not macrophage migration. These results suggest that macrophage
migration is not a trigger of paclitaxel-induced painful neuropathy.
We also found that polaprezinc suppressed the paclitaxel-
induced increase in macrophage migration. Since zinc down-
regulates proinﬂammatory cytokine-induced NF-kB activation (6),
it may also suppress inﬂammatory cytokines induced by paclitaxel
in rat DRG. Also, intrathecal IL-1 receptor antagonist and plasmid
DNA encoding IL-10 have been reported to reverse paclitaxel-
induced mechanical allodynia in rats (3), suggesting thatinﬂammatory cytokines are involved in paclitaxel-induced neu-
ropathy. Recently, zinc supplementation has been reported to
alleviate peripheral neuropathy in diabetic rats (7). Zinc suppresses
inﬂammatory cytokines via the induction of zinc ﬁnger protein A20,
which A20 binds to TNF-receptor-associated factors (TRAFs), in-
hibits Ik kinase-a (IKK-a)/NF-kB, and suppresses the activation of
NF-kB (6). Moreover, chemokines, such as CCL3 and CX3CL-1, have
been reported to be involved in the paclitaxel-induced peripheral
neuropathy (12e14). These chemokines are also controlled by NF-
kB. Therefore, these chemokines may be suppressed by zinc. Taken
together, the induction of A20 and the inhibition of NF-kB signaling
induced by zinc in polaprezinc may inhibit neuronal anti-
inﬂammatory reactions and the development of paclitaxel-
induced mechanical allodynia.
Our results also show that polaprezinc had no effect on
paclitaxel-induced cytotoxicity in tumor cells or on the anti-tumor
effect of paclitaxel in tumor cell-implanted mice.
In conclusion, our results suggest that polaprezinc reduces
paclitaxel-induced peripheral neuropathy without affecting the
anti-tumor activity of paclitaxel.Conﬂicts of interest
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